Cargando…

Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19

Detalles Bibliográficos
Autores principales:	Rappaport, Stephen H., Clark, Jenna M., Delibert, Samantha, Maynard, Kaylee M., Prasad, Paritosh, Kaufman, David C., Pietropaoli, Anthony P., Quill, Caroline M., Groth, Christine M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737599/ https://www.ncbi.nlm.nih.gov/pubmed/32931713 http://dx.doi.org/10.1164/rccm.202006-2511LE

Ejemplares similares

Reply to Rappaport et al.: Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19
por: Dutt, Tina, et al.
Publicado: (2020)

Thromboprophylaxis in COVID-19: Anti-FXa—the Missing Factor?
por: Dutt, Tina, et al.
Publicado: (2020)

The challenge of pharmacological thromboprophylaxis in ICU patients: anti-FXa activity does not constitute the simple solution. Author's reply
por: Hofmaenner, Daniel A., et al.
Publicado: (2022)

Thromboprophylaxis Strategies for Hospitalized Patients With COVID-19
por: Porres-Aguilar, Mateo, et al.
Publicado: (2022)

Thromboprophylaxis for venous thromboembolism prevention in hip fracture patients
Publicado: (2017)

Thromboses and COVID-19: reducing inflammation in addition to thromboprophylaxis
por: Mehta, Puja, et al.
Publicado: (2021)

Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis
por: te Brake, Lindsey H. M., et al.
Publicado: (2019)

Use of a Genetic Variant Related to Circulating FXa (Activated Factor X) Levels to Proxy the Effect of FXa Inhibition on Cardiovascular Outcomes
por: Gill, Dipender, et al.
Publicado: (2020)

Synthesis and evaluation of anthranilamide-based derivatives as FXa inhibitors
por: Huang, Changjiang, et al.
Publicado: (2017)

Intermediate dose thromboprophylaxis in SARS-CoV-2 related venous thrombo embolism
por: Haider, Zahra, et al.
Publicado: (2021)

Thromboprophylaxis in people hospitalized with COVID‐19: Assessing intermediate or standard doses in a retrospective cohort study
por: Andersen, Kathleen M., et al.
Publicado: (2022)

Disparities in Lung-Protective Ventilation in the United States
por: Malnoske, Michelle L, et al.
Publicado: (2022)

Renal function in the ICU: always look both ways before initiating venous thromboprophylaxis
por: Baptista, João Pedro, et al.
Publicado: (2023)

The Treatment of Enteric Fever on the Antiseptic Principle
por: Quill, R. H.
Publicado: (1895)

In silico Discovery of Novel FXa Inhibitors by Pharmacophore Modeling and Molecular Docking
por: Pu, Yinglan, et al.
Publicado: (2017)

Reply to te Brake et al.: Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis
por: Velásquez, Gustavo E., et al.
Publicado: (2019)

Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation
por: Wang, Wenzhi, et al.
Publicado: (2016)

Novel FXa Inhibitor Identification through Integration of Ligand- and Structure-Based Approaches
por: Lagos, Carlos F., et al.
Publicado: (2017)

Characteristics of FXa-storing platelets in hemophilia B mice and the influence of alcohol on the platelets
por: Han, Wenwen, et al.
Publicado: (2023)

Thromboprophylaxis in COVID‐19: Weight and severity adjusted intensified dosing
por: Engelen, Matthias M., et al.
Publicado: (2022)

Venous Thromboprophylaxis in Spine Surgery
por: Alvarado, Anthony M., et al.
Publicado: (2019)

Standard- versus intermediate-dose enoxaparin for anti-factor Xa guided thromboprophylaxis in critically ill patients with COVID-19
por: Hamilton, David Oliver, et al.
Publicado: (2021)

Antiprothrombin antibodies induce platelet activation: A possible explanation for anti‐FXa therapy failure in patients with antiphospholipid syndrome?
por: Chayoua, Walid, et al.
Publicado: (2021)

Edoxaban Exerts Antioxidant Effects Through FXa Inhibition and Direct Radical-Scavenging Activity
por: Narita, Yuki, et al.
Publicado: (2019)

Novel Isosteviol-Based FXa Inhibitors: Molecular Modeling, In Silico Design and Docking Simulation
por: Gackowski, Marcin, et al.
Publicado: (2023)

Management of perioperative thromboprophylaxis for surgery following COVID-19: an expert-panel survey
por: Ferrandis, Raquel, et al.
Publicado: (2021)

Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes
por: Galtier, Jean, et al.
Publicado: (2021)

An Integrated Approach to the Exposome: Rappaport and Lioy Respond
por: Rappaport, Stephen M., et al.
Publicado: (2012)

Antibodies to FXa and thrombin in patients with SLE differentially regulate C3 and C5 cleavage
por: McDonnell, Thomas, et al.
Publicado: (2022)

Direct Oral FXa Inhibitors Binding to Human Serum Albumin: Spectroscopic, Calorimetric, and Computational Studies
por: Mariño-Ocampo, Nory, et al.
Publicado: (2023)

Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy
por: Demchuk, Andrew M., et al.
Publicado: (2021)

Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients
por: Jonmarker, Sandra, et al.
Publicado: (2020)

Weight-adjusted dosing of tinzaparin for thromboprophylaxis in obese medical patients
por: Pfrepper, Christian, et al.
Publicado: (2023)

Rivaroxaban, a specific FXa inhibitor, improved endothelium-dependent relaxation of aortic segments in diabetic mice
por: Pham, Phuong Tran, et al.
Publicado: (2019)

Optimization of Heparin Monitoring with Anti-FXa Assays and the Impact of Dextran Sulfate for Measuring All Drug Activity
por: Amiral, Jean, et al.
Publicado: (2021)

Thromboprophylaxis after bariatric surgery
por: Almarshad, Feras M., et al.
Publicado: (2020)

Caution advised when considering “Exceptional” extended or single dose COVID-19 vaccination strategies
por: Hamidian Jahromi, Alireza, et al.
Publicado: (2021)

Acute high-risk pulmonary embolism requiring thrombolytic therapy in a COVID-19 pneumonia patient despite intermediate dosing deep vein thromboprophylaxis
por: Salam, Shameen, et al.
Publicado: (2020)

Quantitative Structure–Activity Relationship Analysis of Isosteviol-Related Compounds as Activated Coagulation Factor X (FXa) Inhibitors
por: Gackowski, Marcin, et al.
Publicado: (2022)

A Longitudinal Study of Thrombosis and Bleeding Outcomes With Thromboprophylaxis in Pregnant Women at Intermediate and High Risk of VTE
por: Schapkaitz, E., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_k71cg6cee2kfvmfgsmn0ul4013